|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- |||| tradipitant (VLY-686) / Vanda
Trial completion: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Jun 3, 2015
P2, N=69, Completed, Sponsor: Vanda Pharmaceuticals
Recruiting --> Completed
- tacrolimus XR / Generic mfg.
Trial completion, Trial primary completion date: Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients (clinicaltrials.gov) - May 29, 2015
P2, N=9, Completed, Sponsor: UMC Utrecht
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jan 2014
- ||| timapiprant (OC000459) / Chiesi
Enrollment closed, Trial primary completion date: Effect of OC000459 on Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - May 26, 2015
P2, N=200, Active, not recruiting, Sponsor: Atopix Therapeutics, Ltd.
Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jan 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Aug 2015
- Enrollment change: Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions (clinicaltrials.gov) - May 22, 2015
P1/2, N=28, Terminated, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Aug 2015 N=50 --> 28
- | rosiptor (AQX-1125) / Neoleukin Therap
Enrollment closed: KINSHIP: Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis (clinicaltrials.gov) - May 22, 2015
P2, N=50, Active, not recruiting, Sponsor: Aquinox Pharmaceuticals, Inc.
N=50 --> 28 Recruiting --> Active, not recruiting
- |||| Zalain (sertaconazole) / Elder Pharma
Trial completion: Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis (clinicaltrials.gov) - May 20, 2015
P2, N=70, Completed, Sponsor: Spirig Pharma Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Enrollment open: TREBLE: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - May 12, 2015
P2, N=200, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Not yet recruiting --> Recruiting
- recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
Trial primary completion date, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - May 8, 2015
P2, N=6, Recruiting, Sponsor: Edimer Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Dec 2015
- Trial completion: Regulatory T Cells (Tregs) in Polymorphic Light Eruption (clinicaltrials.gov) - May 7, 2015
P=N/A, N=92, Completed, Sponsor: Medical University of Graz
Trial primary completion date: Oct 2014 --> Dec 2015 Recruiting --> Completed
- Altabax (retapamulin) / GSK, Almirall
Enrollment change: Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy (clinicaltrials.gov) - May 6, 2015
P4, N=0, Withdrawn, Sponsor: St. Luke's-Roosevelt Hospital Center
Recruiting --> Completed N=60 --> 0
- Trial primary completion date: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=40, Recruiting, Sponsor: University of Rochester
N=60 --> 0 Trial primary completion date: Dec 2014 --> Dec 2015
- Trial completion, Phase classification, Enrollment change, Trial primary completion date: Molecular and Cellular Characterization of Spongiotic Dermatitis (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=31, Completed, Sponsor: University of California, Davis
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=50 --> 31 | Trial primary completion date: Dec 2011 --> Dec 2012
- ||||| Eucrisa (crisaborole) / Pfizer
Enrollment closed: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 21, 2015
P3, N=750, Active, not recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=50 --> 31 | Trial primary completion date: Dec 2011 --> Dec 2012 Recruiting --> Active, not recruiting
- ||||| Eucrisa (crisaborole) / Pfizer
Enrollment closed: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Apr 21, 2015
P3, N=750, Active, not recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion, Phase classification, Enrollment change, Trial primary completion date: Effectiveness of Melatonin for Sleep Disturbances in Children With Atopic Dermatitis (clinicaltrials.gov) - Apr 20, 2015
P2/3, N=48, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | Phase classification: PN/A --> P2/3 | N=40 --> 48 | Trial primary completion date: Dec 2013 --> Apr 2013
- Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=200, Recruiting, Sponsor: University of California, Davis
Recruiting --> Completed | Phase classification: PN/A --> P2/3 | N=40 --> 48 | Trial primary completion date: Dec 2013 --> Apr 2013 Trial primary completion date: Jan 2015 --> Jan 2025
- |||| fevipiprant (QAW039) / Novartis
Trial completion: Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. (clinicaltrials.gov) - Apr 15, 2015
P2, N=103, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2015 --> Jan 2025 Active, not recruiting --> Completed
- Trial initiation date, Trial termination, IO biomarker: The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=240, Terminated, Sponsor: Mead Johnson Nutrition
Active, not recruiting --> Completed Initiation date: Nov 2013 --> Apr 2015 | Not yet recruiting --> Terminated; Investigators don't want to conduct this study as time is limited.
- ||| Trial completion, Enrollment change, Trial primary completion date: Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=409, Completed, Sponsor: Northwestern University
Initiation date: Nov 2013 --> Apr 2015 | Not yet recruiting --> Terminated; Investigators don't want to conduct this study as time is limited. Recruiting --> Completed | N=576 --> 409 | Trial primary completion date: Jun 2015 --> Jun 2012
- | Trial primary completion date: Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients (clinicaltrials.gov) - Apr 14, 2015
P3, N=30, Recruiting, Sponsor: Mahidol University
Recruiting --> Completed | N=576 --> 409 | Trial primary completion date: Jun 2015 --> Jun 2012 Trial primary completion date: Jul 2015 --> Dec 2015
- tacrolimus topical / Generic mfg.
Enrollment change: Evaluation to Assess the Long Term Safety of Tacrolimus Ointment for Atopic Dermatitis (clinicaltrials.gov) - Apr 7, 2015
P4, N=0, Withdrawn, Sponsor: University of California, Davis
Trial primary completion date: Jul 2015 --> Dec 2015 N=20 --> 0
- Enrollment closed, IO biomarker: ADRN Barrier/Immunoprofiling Exploratory Pilot Study (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=180, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=20 --> 0 Recruiting --> Active, not recruiting
- ||| Trial completion, Trial primary completion date: Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=60, Completed, Sponsor: Genetic Disease Investigators
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Apr 2015
- || Ilaris (canakinumab) / Novartis
Trial completion: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Apr 3, 2015
P3, N=17, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Apr 2015 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=21, Completed, Sponsor: Genetic Disease Investigators
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2011 --> Apr 2015
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
Enrollment closed: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Mar 19, 2015
P1/2, N=30, Active, not recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Oct 2011 --> Apr 2015 Recruiting --> Active, not recruiting
- | Trial completion: Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonatal Period (clinicaltrials.gov) - Mar 17, 2015
P3, N=180, Completed, Sponsor: Chang Gung Memorial Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment open: A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (clinicaltrials.gov) - Mar 17, 2015
P0, N=44, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Trial completion, Enrollment change, Trial primary completion date: A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis (clinicaltrials.gov) - Mar 12, 2015
P1/2, N=62, Completed, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=24 --> 62 | Trial primary completion date: Mar 2015 --> Dec 2014
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA (clinicaltrials.gov) - Mar 11, 2015
P2/3, N=34, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed | N=24 --> 62 | Trial primary completion date: Mar 2015 --> Dec 2014 Recruiting --> Active, not recruiting
- Enrollment change, Trial termination: A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa (clinicaltrials.gov) - Mar 10, 2015
P4, N=3, Terminated, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Active, not recruiting N=18 --> 3 | Recruiting --> Terminated
- || Ilaris (canakinumab) / Novartis
Trial primary completion date: B-Confident: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
N=18 --> 3 | Recruiting --> Terminated Trial primary completion date: Dec 2014 --> Dec 2015
- Trial completion, IO biomarker: VIDATOPIC: Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (clinicaltrials.gov) - Mar 3, 2015
P=N/A, N=101, Completed, Sponsor: Pontificia Universidad Catolica de Chile
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed
- |||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment open: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Feb 26, 2015
P2, N=184, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis (clinicaltrials.gov) - Feb 21, 2015
P=N/A, N=24, Recruiting, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Stelara (ustekinumab) / J&J
Trial completion: A Study of Ustekinumab (STELARA (clinicaltrials.gov) - Feb 19, 2015
P2, N=79, Completed, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Trial primary completion date: TREBLE: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Feb 15, 2015
P2, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Dec 2016
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2017 --> Dec 2016 Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Aug 2015 --> Mar 2015
- | Trial completion, Trial primary completion date: Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD) (clinicaltrials.gov) - Feb 2, 2015
P1, N=30, Completed, Sponsor: LEO Pharma
Trial primary completion date: Aug 2015 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - Jan 30, 2015
P2, N=120, Recruiting, Sponsor: Bayer
Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Mar 2016 --> Jan 2017
- |||| Eucrisa (crisaborole) / Pfizer
Trial primary completion date: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Trial primary completion date: Mar 2016 --> Jan 2017 Trial primary completion date: Feb 2015 --> Jul 2015
- |||| Eucrisa (crisaborole) / Pfizer
Trial primary completion date: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P2 trial: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P2, N=184, Not yet recruiting, Sponsor: MedImmune LLC
- Enrollment open: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=28, Recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Feb 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- | rosiptor (AQX-1125) / Neoleukin Therap
Enrollment open: KINSHIP: Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis (clinicaltrials.gov) - Jan 23, 2015
P2, N=50, Recruiting, Sponsor: Aquinox Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=24, Not yet recruiting, Sponsor: Seoul National University Hospital
- Clinical: A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (clinicaltrials.gov) - Jan 22, 2015
P0, N=44, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Trial completion, Trial primary completion date: Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream (clinicaltrials.gov) - Jan 22, 2015
P1, N=23, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Nov 2014
- ||||| lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
New P2 trial: TREBLE: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 18, 2015
P2, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche